iSTAR Medical’s MINIject maintains exceptional results in first-in-human trial one year post-surgery (STAR-I)

Wavre, Belgium: 19 December 2018 - iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced exceptional one-year results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial, for the MINIjectTM device in a standalone setting. Results continue to show that MINIject is safe and highly effective in achieving significant intraocular pressure (IOP) reduction, as well as easing medication burden in glaucoma patients.

The STAR-I trial demonstrated that the implantation of MINIject resulted in an average 32.6% IOP reduction to a mean of 15.6 mmHg at one year. In addition, 75% of patients were able to discontinue topical medication usage and remained medication-free at one year. There were no serious ocular adverse events and no patient required subsequent glaucoma surgery.

More info on iSTAR Medical's website.


Next > Confo Therapeutics announces exclusive, worldwide license agreement with VIB for Powerful Novel Structure Determination Technology

Previous > UK NICE recommends use of Sequana's alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements